RHYTHM PHARMACEUTICALS, INC. (RYTM) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 239.92M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 26.39M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $239.92M | $26.39M | (m) |
| 2026-03-31 | (m) | $217.16M | $23.00M | (m) |
| 2025-12-31 | (m) | $189.76M | $19.49M | (m) |
| 2025-09-30 | (m) | $174.33M | $18.48M | (m) |
| 2025-06-30 | (m) | $156.29M | $16.81M | (m) |
| 2025-03-31 | (m) | $136.86M | $14.21M | (m) |
| 2024-12-31 | (m) | $130.13M | $13.37M | (m) |
| 2024-09-30 | (m) | $112.53M | $12.81M | (m) |
| 2024-06-30 | (m) | (m) | $11.40M | (m) |
| 2024-03-31 | (m) | (m) | $10.69M | (m) |
| 2023-12-31 | (m) | $77.43M | $9.30M | (m) |
| 2023-09-30 | (m) | (m) | $7.10M | (m) |
| 2022-12-31 | (m) | $23.64M | $2.13M | (m) |
| 2021-12-31 | (m) | $3.15M | $599.00K | (m) |
| 2018-12-31 | (m) | $0.00 | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |